A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker

Pedro N. Aguiar, Ilka Lopes Santoro, Hakaru Tadokoro, Gilberto De Lima Lopes, Bruno Andraus Filardi, Pedro Oliveira, Pedro Castelo-Branco, Giannis Mountzios, Ramon Andrade De Mello

Research output: Contribution to journalArticle

Abstract

Background: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.

Original languageEnglish (US)
Pages (from-to)1011-1019
Number of pages9
JournalImmunotherapy
Volume8
Issue number9
DOIs
StatePublished - Sep 1 2016

Keywords

  • lung cancer
  • meta-analysis
  • nivolumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker'. Together they form a unique fingerprint.

  • Cite this

    Aguiar, P. N., Santoro, I. L., Tadokoro, H., De Lima Lopes, G., Filardi, B. A., Oliveira, P., Castelo-Branco, P., Mountzios, G., & De Mello, R. A. (2016). A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. Immunotherapy, 8(9), 1011-1019. https://doi.org/10.2217/imt-2016-0032